<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        59-29-03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2003
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ORGALUTRAN 0.25MG\0.5ML SYRINGE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        GANIRELIX ACETATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        710.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="VETTER PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            VETTER PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ORGANON
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H01CC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p style="margin-right:20.7pt">Orgalutran contains the active substance ganirelix and belongs to a group of medicines called &ldquo;anti-gonadotrophin-releasing hormones&rdquo; which act against the actions of the natural gonadotrophin releasing hormone (GnRH). GnRH regulates the release of gonadotrophins (luteinising hormone (LH) and follicle stimulating hormone (FSH)).</p><p style="margin-right:15.9pt">Gonadotrophins play an important role in human fertility and reproduction. In women, FSH is needed for the growth and development of follicles in the ovaries. Follicles are small round sacs that contain the egg cells. LH is needed to release the mature egg cells from the follicles and ovaries (i.e. ovulation). Orgalutran inhibits the action of GnRH, resulting in suppression of the release of especially LH.</p><p>&nbsp;</p><p><u>Orgalutran is used for</u></p><p style="margin-right:19.2pt">In women undergoing assisted reproduction techniques, including <em>in</em><em> vitro </em>fertilisation (IVF) and other methods, occasionally ovulation may occur too early causing a significant reduction in the chance of getting pregnant. Orgalutran is used to prevent the premature LH surge that might cause such a premature release of egg cells.</p><p>&nbsp;</p><p style="margin-right:20.7pt">In clinical studies Orgalutran was used with recombinant follicle stimulating hormone (FSH) or corifollitropin alfa, a follicle stimulant with a long duration of action.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Orgalutran</p><p style="margin-left:32.8pt; margin-right:56.3pt; text-indent:-27.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are allergic to ganirelix or any of the other ingredients of this medicine (listed in section 6);</p><p style="margin-left:34.1pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are hypersensitive to gonadotrophin releasing hormone (GnRH) or a GnRH analogue.</p><p style="margin-left:34.1pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have a moderate or severe kidney or liver disease;</p><p style="margin-left:34.1pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are pregnant or breast-feeding.</p><p>&nbsp;</p><p>Warnings and precautions</p><p style="margin-left:5.75pt; margin-right:0in"><strong>Talk to your doctor, pharmacist or nurse before using Orgalutran</strong></p><p style="margin-right:37.45pt; text-align:justify">&nbsp;</p><p style="margin-right:37.45pt; text-align:justify"><u>Allergic reactions</u></p><p style="margin-right:37.45pt; text-align:justify">if you have an active allergic condition, please tell your doctor. Your doctor will decide, depending on the severity, if additional monitoring is required during treatment. Cases of allergic reactions have been reported, as early as with the first dose.</p><p style="margin-right:37.45pt; text-align:justify">&nbsp;</p><p style="margin-right:37.45pt; text-align:justify"><u>Latex allergy</u></p><p style="margin-right:36.75pt">The needle cover of this medicine contains natural rubber latex which may cause allergic reactions.</p><p style="margin-right:36.75pt">&nbsp;</p><p style="margin-right:36.75pt"><u>Ovarian hyperstimulation syndrome (OHSS)</u></p><p style="margin-right:5.65pt">During or following hormonal stimulation of the ovaries, ovarian hyperstimulation syndrome may develop. This syndrome is related to the stimulation procedure with gonadotrophins. Please refer to the Package Leaflet of the gonadotrophin-containing medicine prescribed for you.</p><p style="margin-right:5.65pt">&nbsp;</p><p style="margin-right:5.65pt"><u>Multiple births or birth defects</u></p><p style="margin-right:5.65pt">The incidence of congenital malformations after assisted reproduction techniques may be slightly higher than after spontaneous conceptions. This slightly higher incidence is thought to be related to characteristics of the patients undergoing fertility treatment (e.g. age of the woman, sperm characteristics) and to the higher incidence of multiple gestations after assisted reproduction techniques. The incidence of congenital malformations after assisted reproduction techniques using Orgalutran is not different from that after using other GnRH analogues in the course of assisted reproduction techniques.</p><p style="margin-right:5.65pt">&nbsp;</p><p style="margin-right:5.65pt"><u>Pregnancy complications</u></p><p style="margin-right:13.65pt">There is a slightly increased risk of pregnancy outside of the uterus (an ectopic pregnancy) in women with damaged fallopian tubes.</p><p style="margin-right:13.65pt">&nbsp;</p><p style="margin-right:13.65pt"><u>Women weighing less than 50 kg or more than 90 kg</u></p><p style="margin-right:23.15pt">The efficacy and safety of Orgalutran has not been established in women weighing less than 50 kg or more than 90 kg. Ask your doctor for further information.</p><p>&nbsp;</p><p>Children and adolescents</p><p>There is no relevant use of Orgalutran in children or adolescents. .</p><p>&nbsp;</p><p>Other medicines and Orgalutran</p><p style="margin-right:12.1pt">Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.</p><p>&nbsp;</p><p>Pregnancy, breast-feeding and fertility</p><p style="margin-right:12.1pt">Orgalutran should be used during controlled ovarian stimulation for assisted reproduction techniques (ART). Do not use Orgalutran during pregnancy and breast-feeding.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Driving and using machines</p><p>The effects of Orgalutran on ability to drive and use machines have not been studied.</p><p>&nbsp;</p><p style="margin-left:5.75pt"><strong>Orgalutran</strong><strong> contains sodium</strong></p><p style="margin-left:5.75pt">Orgalutran contains less than 1 mmol sodium (23 mg) per injection, i.e. essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:12.1pt">Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p style="margin-left:5.75pt; margin-right:12.1pt">Orgalutran is used as part of the treatment for assisted reproduction techniques (ART) including <em>in- vitro </em>fertilisation (IVF).</p><p style="margin-left:5.75pt; margin-right:7.75pt; text-align:justify">Ovarian stimulation with follicle stimulating hormone (FSH) or corifollitropin may start at day 2 or 3 of your period. Orgalutran (0.25 mg) should be injected just under the skin once daily, starting on day 5 or day 6 of stimulation. Based on your ovarian response, your doctor may decide to start on another day.</p><p style="margin-right:23.15pt">Orgalutran and FSH should be administered approximately at the same time. However, the preparations should not be mixed and different injection sites are to be used.</p><p>&nbsp;</p><p style="margin-right:10.0pt">Daily treatment with Orgalutran should be continued up to the day that sufficient follicles of adequate size are present. Final maturation of the egg cells in the follicles can be induced by administering human chorionic gonadotrophin (hCG). The time between two Orgalutran injections as well as the</p><p style="margin-left:5.75pt; margin-right:6.2pt; text-align:justify">time between the last Orgalutran injection and hCG injection should not exceed 30 hours, as otherwise a premature ovulation (i.e. release of egg cells) may occur. Therefore, when <u>injecting Orgalutran in the</u> <u>morning </u>treatment with Orgalutran should be continued throughout the gonadotrophin treatment</p><p style="margin-left:5.75pt; margin-right:8.75pt">period including the day of triggering ovulation. When <u>injecting Orgalutran in the afternoon </u>the last Orgalutran injection should be given in the afternoon prior to the day of triggering ovulation.</p><p>&nbsp;</p><p>Instructions for use</p><p><strong>&nbsp;</strong></p><p style="margin-left:5.75pt"><em>Injection site</em></p><p style="margin-right:6.1pt">Orgalutran is supplied in pre-filled syringes and should be injected slowly, just under the skin, preferably in the upper leg. Inspect the solution before use. Do not use if the solution contains particles or is not clear. If you administer the injections yourself or have it done by your partner, follow the instructions below carefully. Do not mix Orgalutran with any other medicines.</p><p>&nbsp;</p><p style="margin-left:5.75pt"><em>Preparing</em><em> the injection site</em></p><p style="margin-left:5.75pt; margin-right:30.45pt; text-align:justify">Wash your hands thoroughly with soap and water. Swab the injection site with a disinfectant (for example alcohol) to remove any surface bacteria. Clean about 5 cm (two inches) around the point where the needle will go in and let the disinfectant dry for at least one minute before proceeding.</p><p>&nbsp;</p><p style="margin-left:5.75pt"><em>Inserting the needle</em></p><p style="margin-left:5.75pt; margin-right:6.1pt">Remove needle cover. Pinch up a large area of skin between finger and thumb. Insert the needle at the base of the pinched-up skin at an angle of 45&deg; to the skin surface. Vary the injection site with each injection.</p><p>&nbsp;</p><p style="margin-left:5.75pt"><em>Checking the correct needle position</em></p><p style="margin-left:5.75pt; margin-right:6.1pt">Gently draw back the plunger to check if the needle is positioned correctly. Any blood drawn into the syringe means the needle tip has penetrated a blood vessel. If this happens, do not inject Orgalutran, but remove the syringe, cover the injection site with a swab containing disinfectant and apply pressure; bleeding should stop in a minute or two. Do not use this syringe and dispose of it properly. Start again with a new syringe.</p><p>&nbsp;</p><p style="margin-left:5.75pt"><em>Injecting the solution</em></p><p style="margin-left:5.75pt; margin-right:6.1pt">Once the needle has been correctly placed, depress the plunger slowly and steadily, so the solution is correctly injected and the skin tissues are not damaged.</p><p>&nbsp;</p><p style="margin-left:5.75pt"><em>Removing the syringe</em></p><p style="margin-right:34.65pt">Pull the syringe out quickly and apply pressure to the site with a swab containing disinfectant. Use the pre-filled syringe only once.</p><p>&nbsp;</p><p>If you use more Orgalutran than you should</p><p>Contact your doctor.</p><p>&nbsp;</p><p>&nbsp;</p><p>If you forget to use Orgalutran</p><p style="margin-left:5.75pt; margin-right:144.15pt">If you realise that you forgot a dose, administer it as soon as possible. Do not inject a double dose to make up for a forgotten dose.</p><p style="margin-right:8.75pt">If you are more than 6 hours late (so the time between two injections is longer than 30 hours) administer the dose as soon as possible <strong>and </strong>contact your doctor for further advice.</p><p>&nbsp;</p><p>If you stop using Orgalutran</p><p style="margin-right:6.1pt">Do not stop using Orgalutran unless advised to by your doctor, as this may affect the outcome of your treatment.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The chance of having a side effect is described by the following categories:</p><p>&nbsp;</p><p style="margin-right:12.1pt"><strong>Very common: may affect more than 1 in 10 women</strong></p><p style="margin-left:41.75pt; margin-right:12.1pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Local skin reactions at the site of injection (predominantly redness, with or without swelling). The local reaction normally disappears within 4 hours of administration.</p><p style="margin-right:12.1pt"><strong>&nbsp;</strong></p><p style="margin-right:12.1pt"><strong>Uncommon: may affect up to 1 in 100 women</strong></p><p style="margin-left:41.75pt; margin-right:12.1pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Headache</p><p style="margin-left:41.75pt; margin-right:12.1pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Nausea</p><p style="margin-left:41.75pt; margin-right:12.1pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Malaise</p><p style="margin-right:12.1pt"><strong>&nbsp;</strong></p><p style="margin-right:12.1pt"><strong>Very rare: may affect up to 1 in 10,000 women</strong></p><p style="margin-left:41.75pt; margin-right:12.1pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->More widespread possibly allergic reactions have been observed, as early as with the first dose.</p><p style="margin-left:41.75pt; margin-right:12.1pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Worsening of a pre-existing rash (eczema) has been reported in one subject after the first Orgalutran dose.</p><p>&nbsp;</p><p style="margin-right:6.7pt">In addition, side effects are reported which are known to occur with controlled ovarian hyperstimulation treatment (e.g. abdominal pain, ovarian hyperstimulation syndrome (OHSS), ectopic pregnancy (when the embryo develops outside the womb) and miscarriage (see the patient information leaflet of the FSH-containing preparation you are treated with)).</p><p>&nbsp;</p><p style="margin-right:6.7pt"><strong>Reporting of side effects</strong></p><p style="margin-right:6.7pt">If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in this leaflet. You can also report side effects directly via &ldquo;The National Pharmacovigilance and Drug Safety Centre (NPC), SFDA&rdquo;. By reporting side effects you can help provide more information on the safety of this</p><p style="margin-right:6.7pt">medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:23.15pt">Keep this medicine out of the sight and reach of children.</p><p style="margin-right:23.15pt">Do not use this medicine after the expiry date which is stated on the carton and on the label after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store below 30&deg;C.</p><p>Do not freeze.</p><p>Store in the original package, in order to protect from light.</p><p>&nbsp;</p><p style="margin-right:23.15pt">Inspect the syringe before use. Use only syringes with clear, particle-free solutions and from undamaged containers.</p><p>&nbsp;</p><p style="margin-right:12.1pt">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Orgalutran contains</p><p style="margin-left:34.1pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The active substance is ganirelix (0.25 mg in 0.5 mL solution).</p><p>The other ingredients are acetic acid, mannitol, water for injections. The pH (a measurement of the acidity) may have been adjusted with sodium hydroxide and acetic acid</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Orgalutran is a clear and colourless aqueous solution for injection. The solution is ready for use and intended for subcutaneous administration. The needle cover contains natural rubber latex.

Orgalutran is available in packs of 1 or 5 pre-filled syringes.
 
Not all pack sizes may be marketed


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder and Manufacturer</p><p style="margin-right:272.05pt"><u>Marketing Authorization Holder</u> Merck Sharp &amp; Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU</p><p>United Kingdom</p><p>&nbsp;</p><p><u>Manufacturer</u></p><p style="margin-right:1.0pt">Vetter Pharma- Fertigung GmbH &amp; Co. KG, Schutzenstrasse 87, 99 and 101, 88212, Ravensburg, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in Jan 2017
Version No. (02)

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي&nbsp; أورجالوتران على المادة الفعالة جانيرليكس و &nbsp;ينتمي إلى فئة من الأدوية تُسمى &quot;مضادات الهرمونات المفرزة لمادة جونادوتروفين&quot; (موجهة الغدد التناسلية) التي تثبط عمل الهرمون الطبيعي الذي يُفرز مادة جوناداتروفين (GnRH). يعمل الهرمون الطبيعي المفرز لمادة جوناداتروفين على تنظيم إفراز جونادوتروفين (الهرمون الملوتن (LH) والهرمون المنبه للجريب (FSH). تقوم موجهات الغدد التناسلية (جونادوتروفين) بدور مهم في الخصوبة والتناسل للانسان. ففي النساء؛ يكون الهرمون المنبه للجريب (FSH) &nbsp;ضروريا لنمو وتطور الجريبات في المبايض. والجريبات عبارة عن حويصلات صغيرة تحتوي على خلايا البويضة. ويكون الهرمون الملوتن (LH) &nbsp;ضروريا لإطلاق خلايا البويضة الناضجة من الجريبات والمبايض (أي عملية التبويض). ويعمل الدواء أورجالوتران &nbsp;على منع عمل الهرمون الطبيعي المفرز لموجهات الغدد التناسلية GnRH) )، مما يؤدي إلى تثبيط إفراز هرمون الملوتن (LH) &nbsp;بشكل خاص.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><u>دواعي استخدام أورجالوتران </u></strong><strong><u>:</u></strong></p><p dir="RTL">في النساء اللواتي يخضعن لتقنيات المساعدة على الإنجاب، بما في ذلك التخصيب &nbsp;<em>في المختبر</em> (IVF) وغيره من الوسائل، أحيانا قد تحدث الإباضة في وقت مبكر جدًا مما يسبب إنخفاضاً في فرصة حدوث حمل. ويُستخدم أورجالوتران &nbsp;لمنع التدفق المبكر للهرمون الملوتن(LH) &nbsp;الذي قد يسبب الإطلاق المبكر لخلايا البويضة.</p><p dir="RTL">في الدراسات السريرية استُخدِم أورجالوتران &nbsp;مع هرمون مؤتلف منبه للجريب (FSH) &nbsp;أو كوريفوليتروبين ألفا، وهو منبه الجريب ذو مفعول طويل المدى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استخدام أورجالوتران </strong></p><p style="margin-right:27.0pt; text-indent:-27.0pt" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الحساسية تجاه مادة جانيرليكس &nbsp;أو أيٍ من المكونات الأخرى في هذا الدواء (المذكورة في القسم ٦)،</p><p style="margin-right:0in; text-indent:0in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->فرط الحساسية تجاه الهرمون المفرز لموجهة الغدد التناسلية (GnRH) أو ما شابهه.</p><p style="margin-right:0in; text-indent:0in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الإصابة بمرض متوسط أو خطير في الكلى أو مرض في الكبد،</p><p style="margin-right:0in; text-indent:0in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الحمل أو الرضاعة الطبيعية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">ينبغي التحدث مع الطبيب أو الصيدلي أو الممرضة قبل استخدام أورجالوتران .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الحساسية</u></p><p dir="RTL">في حالة حدوث رد فعل تحسسي نشط؛ يُرجى إخبار الطبيب بذلك. سوف يقرر الطبيب - حسب درجة خطورة الحالة - هل تستدعي الحالة مراقبة إضافية أثناء العلاج أم لا. تم الإبلاغ عن حدوث حالات حساسية مع الجرعة الاولى مباشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>حساسية اللاتكس (المطاط الطبيعي)</u></p><p dir="RTL">يحتوي غطاء الإبرة في هذا الدواء على مادة اللاتكس المطاط الطبيعي التي قد تسبب حساسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>متلازمة فرط التحفيز الهرموني للمبيض (</u><u>OHSS</u><u>)</u></p><p dir="RTL">أثناء أو في أعقاب التحفيز الهرموني للمبايض، قد تحدث متلازمة فرط تحفيز المبيض. ترتبط هذه المتلازمة بإجراء التحفيز مع موجهات الغدد التناسلية. يُرجى الرجوع إلى نشرة العبوة للدواء المحتوي على موجهة الغدد التناسلية (جونادوتروفين) الذي وُصف لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تعدد الولادة أو عيوب خلقية </u></p><p dir="RTL">قد يكون معدل حدوث التشوهات الخلقية بعد استخدام تقنيات المساعدة على الإنجاب أعلى قليلاً منه بعد استخدام وسائل الحمل التلقائية. ويعتقد أن هذا المعدل المرتفع قليلاً مرتبط بخصائص المرضى الذين يخضعون لعلاج الخصوبة (مثل سن المرأة، وخصائص الحيوانات المنوية) وأيضًا بارتفاع معدل حدوث حمل متعدد بعد استخدام تقنيات المساعدة على الإنجاب. لا يختلف معدل حدوث التشوهات الخلقية بعد استخدام تقنيات المساعدة على الإنجاب باستخدام أورجالوتران &nbsp;اختلافًا كبيرًا عنه بعد استخدام ممثلات هرمون GnRH الأخرى في سياق تقنيات المساعدة على الإنجاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>مضاعفات الحمل</u></p><p dir="RTL">هناك احتمال طفيف لزيادة حدوث حمل خارج الرحم في السيدات المصابات بتلف قنوات فالوب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الإناث بوزن أقل من 50 كلغم أو أكثر من 90 كلغم</p><p dir="RTL">لم يتم التأكد من فعالية وسلامة استخدام أورجالوتران &nbsp;في النساء اللاتي يقل وزنهن عن ٥٠ كلغم أو اللاتي يزيد وزنهن عن ٩٠ كلغم. يُرجى طلب مزيد من المعلومات من الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">ليس هناك داعٍ لاستخدام أورجالوتران &nbsp;في الأطفال أو المراهقين</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وأورجالوتران </strong></p><p dir="RTL">يُرجى إخبار الطبيب أو الصيدلي أو الممرضة إذا كنت تتناولين حاليا - أو تناولت مؤخرا أو قد تتناولين لاحقاً - أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">ينبغي استخدام أورجالوتران &nbsp;أثناء تحفيز المبيض الخاضع للمراقبة للحصول على تقنيات المساعدة على الإنجاب. لا تستخدمي أورجالوتران &nbsp;أثناء الحمل والرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى استشارة الطبيب أو الصيدلي قبل استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة المركبات واستخدام الآلات</strong></p><p dir="RTL">لم تُجر دراسة على تأثير أورجالوتران &nbsp;على القدرة على قيادة المركبات واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي أورجالوتران على الصوديوم</strong></p><p dir="RTL">يحتوي أورجالوتران<strong> </strong>على أقل من ١ ملمول (٢٣ ملغم) لكل حقنة، أي أنه &quot;خالٍ من الصوديوم&quot; بصفة أساسية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ينبغي الحرص دائما على تناول هذا الدواء تماماً حسب إرشادات الطبيب أو الصيدلي. ينبغي استشارة الطبيب أو الصيدلي في حالة عدم التأكد من كيفية الاستخدام.</p><p dir="RTL">يُستخدم أورجالوتران &nbsp;كجزء من العلاج بتقنيات المساعدة على الإنجاب بما في ذلك الإخصاب في المختبر.</p><p dir="RTL">يمكن بدء العلاج بتحفيز المبيض باستخدام الهرمون المنبه للجريب(FSH) &nbsp;أو كوريفوليتروبين في اليوم الثاني أو الثالث من الدورة الشهرية. يجب حقن أورجالوتران &nbsp;(٢٥،٠ ملغم) تحت الجلد مباشرة مرة واحدة يوميا بدء من اليوم الخامس أو السادس من التحفيز. حسب استجابة المبيض؛ قد يقرر الطبيب بدء العلاج في يوم آخر.</p><p dir="RTL">ينبغي استخدام أورجالوتران &nbsp;والهرمون المنبه للجريب (FSH) &nbsp;في وقت واحد تقريبًا. ولكن ينبغي عدم مزج هذه الأدوية ببعضها، وينبغي إجراء الحقن في مواضع مختلفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي الاستمرار في أخذ الجرعات اليومية من أورجالوتران &nbsp;حتى ظهور جريبات كافية ذات حجم مناسب. ويمكن تحفيز النضج النهائي لخلايا البويضة في الجريبات عن طريق أخذ موجهة الغدد التناسلية المشيمية البشرية (اتش سي جي). يجب ألا يتجاوز الوقت الفاصل بين حقنتين من أورجالوتران &nbsp;- وكذلك الوقت الفاصل بين آخر حقنة من أورجالوتران &nbsp;وحقنة موجهة الغدد التناسلية المشيمية البشرية (HCG) &ndash; ٣٠ ساعة، وإلا فقد يحدث تبويض مبكر (إطلاق خلايا البويضة مبكرا). ولذا، عند <u>حقن أورجالوتران &nbsp;في الصباح</u> يجب الاستمرار في العلاج بأورجالوتران &nbsp;طوال مدة العلاج بموجهة الغدد التناسلية بما في ذلك اليوم الذي يبدأ فيه التبويض. وعند <u>حقن أورجالوتران فترة ما بعد الظهر</u> يجب إعطاء الحقنة الأخيرة من أورجالوتران &nbsp;<u>بعد الظهر</u> قبل اليوم الذي يبدأ فيه التبويض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعليمات للإستخدام</strong></p><p dir="RTL"><em><u>موضع الحقن</u></em></p><p dir="RTL">يتوفر أورجالوتران &nbsp;في حقنات معبأة مسبقًا ويجب حقنه ببطء تحت الجلد مباشرة ويُفضل في الجزء العلوي من الرجل. ينبغي اختبار المحلول قبل الاستخدام. لا يُستخدم المحلول إذا كان يحتوي على جزيئات أو كان غير صافٍ. إذا كانت المريضة تأخذ الحقن بنفسها أو بواسطة زوجها؛ فينبغي اتباع التعليمات التالية بعناية. لا تمزَجي أورجالوتران &nbsp;بأي دواء آخر.</p><p dir="RTL"><em><u>تحضير موضع الحقن</u></em></p><p dir="RTL">تُغسل اليدين جيدًا بالماء والصابون. يُنظف موضع الحقن في الجسم بقطعة قطن مبللة بمطهر طبي (كحول مثلاً) لإزالة أي بكتريا على سطح الجلد. تُنظف مساحة ٥ سم (بوصتين) حول النقطة التي ستدخل فيها الإبرة، ويُترك المطهر يجف لمدة دقيقة واحدة قبل إجراء الحقن.</p><p dir="RTL"><em><u>إدخال الإبرة</u></em></p><p dir="RTL">يُنزع غطاء الإبرة. تُمسك منطقة من الجلد بين الإصبعين السبابة والإبهام. تُدخل الإبرة في قاعدة المنطقة الممسوكة من الجلد بزاوية ٤٥ درجة بالنسبة إلى سطح الجلد. ينبغي تغيير موضع الحقن في كل حقنة.</p><p dir="RTL"><em><u>التحقق من وضع الإبرة الصحيح</u></em></p><p dir="RTL">يُسحب مكبس الحقنة برفق للخلف للتحقق من وضع الإبرة بشكل صحيح. في حالة ظهور أي دم داخل الحقنة؛ يعني هذا دخول طرف الإبرة في وعاء دموي. في هذه الحالة؛ لا يُحقن محلول أورجالوتران ، ولكن تُنزع الحقنة، ويُغطى موضع الحقن بقطعة قطن طبي مبللة بمطهر ويُضغط بها على الجلد؛ ومن المفترض أن يتوقف النزيف خلال دقيقة أو دقيقتين. لا تُستخدم هذه الحقنة ويُجب التخلَّص منها بطريقة سليمة. ابدأ عملية الحقن من جديد باستخدام حقنة جديدة.</p><p dir="RTL"><em><u>حقن المحلول</u></em></p><p dir="RTL">بمجرد إدخال الإبرة تحت الجلد بطريقة صحيحة؛ يُضغط على المكبس ببطء وبثبات حتى يتم حقن المحلول بطريقة صحيحة ولا تُصاب أنسجة الجلد بأذى.</p><p dir="RTL"><em><u>نزع الحقنة</u></em></p><p dir="RTL">تُسحب الحقنة بسرعة من الجلد ويُضغط على موضع الحقن بقطعة قطن طبي مبللة بمطهر طبي.</p><p dir="RTL">تُستخدم الحقنة المعبأة مسبقا مرة واحدة فقط.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><em>في حالة تناول جرعة زائدة من أورجالوتران </em></strong></p><p dir="RTL">ينبغي الاتصال بالطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة نسيان جرعة أورجالوتران </strong></p><p dir="RTL">في حالة نسيان جرعة أورجالوتران ؛ ينبغي تناولها في أسرع وقت ممكن.</p><p dir="RTL">لا تُحقن جرعة مزدوجة لتعويض الجرعة الفائتة.</p><p dir="RTL">في حالة التأخر عن موعد أخذ الحقنة بمدة ٦ ساعات (بحيث يكون الوقت الفاصل بين حقنتين أطول من ٣٠ ساعة) ينبغي أخذ الحقنة في أسرع وقت ممكن واستشارة الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة التوقف عن استخدام أورجالوتران </strong></p><p style="margin-left:-.1pt" dir="RTL">يجب عدم التوقف عن استخدام حقن أورجالوتران &nbsp;ما لم ينصح الطبيب بذلك، لأن هذا قد يؤثر على نتيجة العلاج.</p><p style="margin-left:-.1pt" dir="RTL">&nbsp;</p><p style="margin-left:-.1pt" dir="RTL">إذا كان لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، فينبغي استشارة الطبيب أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="margin-right:.5in; text-indent:-.25in" dir="RTL"><!--[if !supportLists]--><strong>1.&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>الأعراض الجانبية المحتملة</strong></p><p dir="RTL">مثل كل الأدوية، يمكن أن يسبب هذا الدواء أعراض جانبية وإن كانت لا تحدث في جميع الأشخاص الذين يستخدمونه.</p><p dir="RTL">يتم وصف فرصة حدوث الأعراض الجانبية حسب الفئات التالية:<br /><br /><strong>شائعة جدا: قد تؤثر على أكثر من 1 من كل 10 نساء</strong></p><p style="margin-right:.5in; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->ردود فعل الجلد في موقع الحقن (في الغالب احمرار، مع أو من دون تورم). ردود الفعل تختفي عادة في غضون 4 ساعات من الحقن.</p><p style="margin-right:.25in" dir="RTL"><strong>شائعة: قد تؤثر على ما يصل إلى 1 في 100 امرأة</strong></p><p style="margin-right:.5in; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->صداع الراس</p><p style="margin-right:.5in; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->الغثيان</p><p style="margin-right:.5in; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->توعك</p><p style="margin-right:.25in" dir="RTL"><br /><strong>نادرة جدا: قد يؤثر على ما يصل إلى 1 في 10،000 امرأة</strong></p><p style="margin-right:.5in; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->ردود فعل تحسسية على نطاق واسع، في وقت مبكر كما هو الحال مع الجرعة الأولى.</p><p style="margin-right:.5in; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->تفاقم الطفح الجلدي (الأكزيما) لدى مريض واحد بعد الجرعة الأولى من أورجالوتران</p><p style="margin-right:.25in" dir="RTL">&nbsp;.</p><p dir="RTL">بالإضافة إلى ذلك، يتم الإبلاغ عن الأعراض الجانبية التي من المعروف أنها تحدث مع علاج فرط تحفيز المبيض الخاضع للمراقبة (مثل ألم في البطن، متلازمة فرط تحفيز المبيض ( OHSS)، الحمل خارج الرحم (عندما يتطور الجنين خارج الرحم)، الإجهاض (انظري نشرة معلومات المريض الخاصة بالمستحضر الدوائي المحتوي على الهرمون المنبه للجريب &nbsp;(FSH) الذي تُعالجين به)).</p><p style="text-align:justify" dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>&nbsp;الابلاغ عن الأعراض الجانبيّة:</u></strong></p><p dir="RTL">في حال التعرّض لأعراض جانبيّة، تحدّث إلى الطبيب أو الصيدلي أو الممرض. يشمل ذلك أي أعراض جانبيّة غير مُدرجة في هذه النشرة. يمكنك الابلاغ عن الأعراض الجانبيّة مباشرة عن طريق &quot; لمركز الوطني للتيقظ والسلامة الدوائية&nbsp;&nbsp; ، التابع لهيئة العامة للغذاء والدواء السعودية&quot;. ومن خلال الابلاغ عن لأعراض الجانبيّة، يُمكنك تأمين المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ بعيدًا عن متناول أيدي ومرأى الأطفال<strong>.</strong></p><p dir="RTL">يُحفظ في درجة حرارة أقل من ٣۰ درجة مئوية.</p><p dir="RTL">لا يُجمد&nbsp; .يُحفظ في العبوة الأصلية لحمايته من الضوء.</p><p dir="RTL">لا يُستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المكتوب على العلبة الكرتونية والملصق بعد الأحرف &quot;EXP&quot; (انتهاء الصلاحية). يشير تاريخ الصلاحية إلى آخر يوم في الشهر المطبوع على العلبة الكرتونية.</p><p dir="RTL"><em>ينبغي التحقق من الحقنة قبل الاستخدام. لا تُستخدم إلا الحقنات التي تحتوي على محلول صافٍ و خالٍ من الجزيئات وذات العبوات غير التالفة.</em></p><p dir="RTL">لا تتخلص من أي أدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لا تحتاج إليها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات أورجالوتران &nbsp;</strong><strong>&nbsp;</strong></p><p style="margin-right:25.65pt; text-indent:-25.65pt" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->المادة الفعالة هي جانيرليكس (25&sbquo;٠ملغم في محلول 5&sbquo;0 مل).</p><p style="margin-right:28.35pt; text-indent:-28.35pt" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->المكونات الأخرى هي: مانيتول ، &nbsp;حمض أسيتك، هيدروكسيد الصوديوم وحمض الأسيتك لتعديل مقياس الحموضة ، ماء للحقن</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أشكال أورجالوتران &nbsp;ومحتويات العبوة</strong></p><p dir="RTL">أورجالوتران &nbsp;عبارة عن محلول سائل للحقن صافٍ وعديم اللون. هذا المحلول جاهز للاستخدام ومعد للحقن تحت الجلد. يحتوي غطاء الإبرة على مادة<strong> اللاتكس المطاط الطبيعي</strong>.</p><p dir="RTL">يتوفر أورجالوتران &nbsp;في عبوات بها حقنة واحدة أو ٥ حقنات معبأة مسبقا.</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><u>الشركة المالكة لحقوق التسويق</u></strong></p><p style="text-align:justify" dir="RTL">ميرك شارب ودوم المحدودة،</p><p style="text-align:justify" dir="RTL">طريق هيرتفورد، هوديسدون، هيرتفوردشاير</p><p style="text-align:justify" dir="RTL">&nbsp;أي أن ١١ ٩ بي يو، المملكة المتحدة</p><p style="text-align:justify" dir="RTL"><strong><u>الشركة المصنعة:</u></strong></p><p style="text-align:justify" dir="RTL">فيتر فارما - فيرتجونج، جي ام بي اتش اند كو. كيه جي، شوتزنستراس ٨٧، ٩٩ و١٠١، ٨٨٢١٢ &nbsp;رافنسبرج، ألمانيا</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة بتاريخ يناير 2017   .الاصدار رقم (2)                     
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Orgalutran 0.25 mg/0.5 ml solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Each pre-filled syringe contains 0.25 mg of ganirelix in 0.5 ml aqueous solution. The active substance ganirelix (INN) is a synthetic decapeptide with high antagonistic activity to the naturally occurring gonadotrophin releasing hormone (GnRH). The amino acids at positions 1, 2, 3, 6, 8 and 10 of the natural GnRH decapeptide have been substituted resulting in N-Ac-D-Nal(2)1, D-pClPhe2, D-Pal(3)3, D-hArg(Et2)6, L-hArg(Et2)8, D-Ala10]-GnRH with a molecular weight of 1570.4.

Excipient with known effect:
This medicinal product contains less than 1 mmol sodium (23 mg) per injection, i.e. essentially
‘sodium-free’.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.

Clear and colourless aqueous solution.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:13.3pt">Orgalutran is indicated for the prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART).</p><p>&nbsp;</p><p style="margin-right:13.3pt">In clinical studies Orgalutran was used with recombinant human follicle stimulating hormone (FSH) or corifollitropin alfa, the sustained follicle stimulant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.75pt; margin-right:9.0pt">Orgalutran should only be prescribed by a specialist experienced in the treatment of infertility. <u>Posology</u></p><p>Orgalutran is used to prevent premature LH surges in women undergoing COH. Controlled ovarian</p><p style="margin-right:23.4pt">hyperstimulation with FSH or corifollitropin alfa may start at day 2 or 3 of menses. Orgalutran (0.25 mg) should be injected subcutaneously once daily, starting on day 5 or day 6 of FSH administration or on day 5 or day 6 following the administration of corifollitropin alfa. The starting</p><p style="margin-left:5.75pt; margin-right:9.0pt">day of Orgalutran is depending on the ovarian response, i.e. the number and size of growing follicles and/or the amount of circulating oestradiol. The start of Orgalutran may be delayed in absence of follicular growth, although clinical experience is based on starting Orgalutran on day 5 or day 6 of stimulation.</p><p style="margin-right:13.3pt">Orgalutran and FSH should be administered approximately at the same time. However, the preparations should not be mixed and different injection sites are to be used.</p><p style="margin-right:9.15pt">FSH dose adjustments should be based on the number and size of growing follicles, rather than on the amount of circulating oestradiol (see section 5.1).</p><p style="margin-left:5.75pt; margin-right:9.15pt">Daily treatment with Orgalutran should be continued up to the day that sufficient follicles of adequate size are present. Final maturation of follicles can be induced by administering human chorionic gonadotrophin (hCG).</p><p>&nbsp;</p><p style="margin-left:5.75pt"><em>Timing of last injection</em></p><p style="margin-right:9.0pt">Because of the half-life of ganirelix, the time between two Orgalutran injections as well as the time between the last Orgalutran injection and the hCG injection should not exceed 30 hours, as otherwise a</p><p style="margin-left:5.75pt; margin-right:13.3pt">premature LH surge may occur. Therefore, when injecting Orgalutran in the morning, treatment with Orgalutran should be continued throughout the gonadotrophin treatment period including the day of triggering ovulation. When injecting Orgalutran in the afternoon the last Orgalutran injection should be given in the afternoon prior to the day of triggering ovulation.</p><p>Orgalutran has shown to be safe and effective in women undergoing multiple treatment cycles.</p><p>&nbsp;</p><p style="margin-right:13.3pt">The need for luteal phase support in cycles using Orgalutran has not been studied. In clinical studies, luteal phase support was given according to study centres&rsquo; practice or according to the clinical protocol.</p><p style="margin-right:13.3pt">&nbsp;</p><p style="margin-right:13.3pt">Special populations</p><p>&nbsp;</p><p style="margin-left:5.75pt"><em>Renal impairment</em></p><p style="margin-right:13.3pt">There is no experience on the use of Orgalutran in subjects with renal impairment, as they were excluded from clinical studies. Therefore, the use of Orgalutran is contraindicated in patients with moderate or severe renal impairment. (see section 4.3).</p><p>&nbsp;</p><p style="margin-left:4.5pt"><em>Hepatic impairment</em></p><p style="margin-left:4.5pt">There is no experience on the use of Orgalutran in subjects with hepatic impairment, as they were</p><p style="margin-left:4.5pt">excluded from clinical studies. Therefore, the use of Orgalutran is contraindicated in patients with</p><p style="margin-left:4.5pt">hepatic impairment (see section 4.3).</p><p style="margin-left:5.75pt"><em>&nbsp;</em></p><p style="margin-left:5.75pt"><em>Paediatric population</em></p><p>There is no relevant use of Orgalutran in the paediatric population.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Method of administration</u></p><p style="margin-right:9.15pt">Orgalutran should be administered subcutaneously, preferably in the upper leg. The injection site should be varied to prevent lipoatrophy. The patient or her partner may perform the injections of Orgalutran themselves, provided that they are adequately instructed and have access to expert advice.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
	Hypersensitivity to gonadotrophin-releasing hormone (GnRH) or any other GnRH analogue.
	Moderate or severe impairment of renal or hepatic function.
	Pregnancy or breast-feeding.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity reaction</u></p><p style="margin-left:0in; margin-right:13.8pt">Special care should be taken in women with signs and symptoms of active allergic conditions. Cases of hypersensitivity reactions, have been reported, as early as with the first dose, during post-marketing surveillance (see section 4.8). In the absence of clinical experience, Orgalutran treatment is not advised in women with severe allergic conditions.</p><p>&nbsp;</p><p><u>Latex allergy</u></p><p style="margin-left:0in; margin-right:9.15pt">The packaging of this medicinal product contains natural rubber latex which may cause allergic reactions (see section 6.5).</p><p>&nbsp;</p><p><u>Ovarian hyperstimulation syndrome (OHSS)</u></p><p style="margin-left:0in; margin-right:23.4pt">Ovarian hyperstimulation syndrome (OHSS) may occur during or following ovarian stimulation. OHSS must be considered an intrinsic risk of gonadotrophin stimulation. OHSS should be treated symptomatically, e.g. with rest, intravenous infusion of electrolyte solutions or colloids and heparin.</p><p>&nbsp;</p><p><u>Ectopic pregnancy</u></p><p style="margin-left:0in; margin-right:14.45pt">Since infertile women undergoing assisted reproduction, and particularly <em>in</em><em> vitro </em>fertilisation (IVF), often have tubal abnormalities the incidence of ectopic pregnancies might be increased. Early ultrasound confirmation that a pregnancy is intrauterine is therefore important.</p><p>&nbsp;</p><p><u>Congenital malformations</u></p><p style="margin-left:0in; margin-right:7.4pt">The incidence of congenital malformations after Assisted Reproductive Technologies (ART) may be higher than after spontaneous conceptions. This is thought to be due to differences in parental characteristics (e.g. maternal age, sperm characteristics) and an increased incidence of multiple gestations. In clinical studies investigating more than 1,000 newborns it has been demonstrated that the incidence of congenital malformations in children born after COH treatment using Orgalutran is comparable with that reported after COH treatment using a GnRH agonist.</p><p style="margin-left:0in; margin-right:7.4pt">&nbsp;</p><p>Women weighing less than 50 kg or more than 90 kg</p><p style="margin-left:0in; margin-right:7.4pt">&nbsp;</p><p style="margin-left:0in; margin-right:7.4pt">The safety and efficacy of Orgalutran have not been established in women weighing less than 50 kg or more than 90 kg (see also section 5.1 and 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed.</p><p>&nbsp;</p><p>The possibility of interactions with commonly used medicinal products, including histamine liberating medicinal products, cannot be excluded.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p>There are no adequate data from the use of ganirelix in pregnant women.</p><p>In animals, exposure to ganirelix at the time of implantation resulted in litter resorption (see section 5.3). The relevance of these data for humans is unknown.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><u>&nbsp;</u></p><p>It is not known whether ganirelix is excreted in breast milk.</p><p>The use of Orgalutran is contraindicated during pregnancy and breast-feeding (see section 4.3).</p><p style="margin-left:5.75pt"><em>&nbsp;</em></p><p style="margin-left:5.75pt"><em>Fertility</em></p><p style="margin-right:35.0pt; text-align:justify">Ganirelix is used in the treatment of women undergoing controlled ovarian hyperstimulation in assisted reproduction programmes. Ganirelix is used to prevent premature LH surges that might otherwise occur in these women during the ovarian stimulation.</p><p>For posology and method of administration, see section 4.2.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:4.5pt; margin-right:0in"><strong>Summary of the safety profile</strong></p><p style="margin-left:4.5pt; margin-right:0in"><strong>&nbsp;</strong></p><p style="margin-right:8.05pt">The table below shows all adverse reactions in women treated with Orgalutran in clinical studies using recFSH for ovarian stimulation. The adverse reactions with Orgalutran using corifollitropin alfa for ovarian stimulation are expected to be similar.</p><p style="margin-right:8.05pt">&nbsp;</p><p style="margin-right:8.05pt">&nbsp;</p><p style="margin-right:8.05pt">&nbsp;</p><p style="margin-right:8.05pt">Tabulated list of adverse reactions</p><p style="margin-right:8.05pt">The adverse reactions are classified according to MedDRA system organ class and frequency; very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1000 to &lt;1/100). The frequency of hypersensitivity reactions (very rare, &lt;1/10,000) has been deduced from post-marketing surveillance.</p><p style="margin-right:8.05pt">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:13.1pt; vertical-align:top; width:137.75pt"><p style="margin-left:5.1pt; margin-right:0in"><strong>System organ class</strong></p></td><td style="border-color:black; height:13.1pt; vertical-align:top; width:88.55pt"><p style="margin-left:5.1pt; margin-right:0in"><strong>Frequency</strong></p></td><td style="border-color:black; height:13.1pt; vertical-align:top; width:238.1pt"><p style="margin-left:5.1pt; margin-right:0in"><strong>Adverse reaction</strong></p></td></tr><tr><td style="border-color:black; height:51.1pt; vertical-align:top; width:137.75pt"><p style="margin-left:5.1pt; margin-right:0in"><em>Immune system disorders</em></p></td><td style="height:51.1pt; vertical-align:top; width:88.55pt"><p style="margin-left:5.1pt; margin-right:0in">Very rare</p></td><td style="height:51.1pt; vertical-align:top; width:238.1pt"><p style="margin-left:5.1pt; margin-right:33.85pt">Hypersensitivity reactions (including various symptoms such as rash, facial swelling and dyspnoea)1</p><p style="margin-left:5.1pt">Worsening of a pre-existing eczema2</p></td></tr><tr><td style="border-color:black; height:25.8pt; vertical-align:top; width:137.75pt"><p style="margin-left:5.1pt; margin-right:0in"><em>Nervous system disorders</em></p></td><td style="height:25.8pt; vertical-align:top; width:88.55pt"><p style="margin-left:5.1pt; margin-right:0in">Uncommon</p></td><td style="height:25.8pt; vertical-align:top; width:238.1pt"><p style="margin-left:5.1pt; margin-right:0in">Headache</p></td></tr><tr><td style="border-color:black; height:25.8pt; vertical-align:top; width:137.75pt"><p style="margin-left:5.1pt; margin-right:0in"><em>Gastrointestinal disorders</em></p></td><td style="height:25.8pt; vertical-align:top; width:88.55pt"><p style="margin-left:5.1pt; margin-right:0in">Uncommon</p></td><td style="height:25.8pt; vertical-align:top; width:238.1pt"><p style="margin-left:5.1pt; margin-right:0in">Nausea</p></td></tr><tr><td style="border-color:black; height:38.4pt; vertical-align:top; width:137.75pt" rowspan="2"><p style="margin-left:5.1pt; margin-right:32.2pt"><em>General disorders and</em><em> </em><em>administration site</em><em> </em><em>conditions</em></p></td><td style="height:38.4pt; vertical-align:top; width:88.55pt"><p style="margin-left:5.1pt; margin-right:0in">Very Common</p></td><td style="height:38.4pt; vertical-align:top; width:238.1pt"><p style="margin-left:5.1pt; margin-right:8.1pt">Local skin reaction at the site of injection (predominantly redness, with or without swelling)3</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:88.55pt"><p style="margin-left:5.1pt; margin-right:0in">Uncommon</p></td><td style="height:17.3pt; vertical-align:top; width:238.1pt"><p style="margin-left:5.1pt; margin-right:0in">Malaise</p></td></tr></tbody></table><p style="margin-right:8.05pt">&nbsp;</p><p>1 Cases have been reported, as early as with the first dose, among patients administered Orgalutran.</p><p>2 Reported in one subject after the first Orgalutran dose.</p><p>3 In clinical studies, one hour after injection, the incidence of at least once a moderate or severe local</p><p>skin reaction per treatment cycle, as reported by patients, was 12 % in Orgalutran treated patients and</p><p>25 % in patients treated subcutaneously with a GnRH agonist. The local reactions generally disappear</p><p>within 4 hours after administration.</p><p>&nbsp;</p><p>Description of selected adverse reactions</p><p style="margin-left:0in; margin-right:9.4pt">Other reported adverse reactions are related to the controlled ovarian hyperstimulation treatment for ART, notably pelvic pain, abdominal distension, OHSS (see also section 4.4), ectopic pregnancy and spontaneous abortion.</p><p style="margin-left:0in; margin-right:9.4pt">&nbsp;</p><p style="margin-left:0in; margin-right:9.4pt">Reporting of suspected adverse reactions</p><p style="margin-left:0in; margin-right:9.4pt">Reporting suspected adverse reactions after authorization of the medicinal product is important. It</p><p style="margin-left:0in; margin-right:9.4pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via :</p><p style="margin-right:9.4pt">&nbsp;</p><p style="margin-right:27.6pt"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To report any side effect(s):</strong></p><p style="margin-left:45.0pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Saudi Arabia: </u></p><p style="text-align:justify">The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p style="text-align:justify">o Fax: +966-11-205-7662</p><p style="text-align:justify">o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.</p><p style="text-align:justify">o Toll free phone: 8002490000</p><p style="text-align:justify">o E-mail: npc.drug@sfda.gov.sa</p><p style="text-align:justify">o Website: www.sfda.gov.sa/npc</p><p style="margin-left:45.0pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Other GCC States: </u></p><p style="text-align:justify">Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose in humans may result in a prolonged duration of action.</p><p style="margin-left:5.75pt; margin-right:8.3pt">No data on acute toxicity of Orgalutran in humans are available. Clinical studies with subcutaneous administration of Orgalutran at single doses up to 12 mg did not show systemic adverse reactions. In acute toxicity studies in rats and monkeys non-specific toxic symptoms such as hypotension and bradycardia were only observed after intravenous administration of ganirelix over 1 and 3 mg/kg, respectively.</p><p>In case of overdose, Orgalutran treatment should be (temporarily) discontinued.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:9.4pt">Pharmacotherapeutic group: Pituitary and hypothalamic hormones and analogues, anti-gonadotrophin- releasing hormones, ATC code: H01CC01.</p><p style="margin-right:9.4pt">&nbsp;</p><p style="margin-right:9.4pt">Mechanism of action</p><p>&nbsp;</p><p style="margin-right:8.3pt">Orgalutran is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitive binding to the GnRH receptors in the pituitary gland. As a result a rapid, profound, reversible suppression of endogenous gonadotrophins occurs, without initial stimulation as induced by GnRH agonists. Following administration of multiple doses of 0.25 mg Orgalutran to female volunteers serum LH, FSH and E2&nbsp;concentrations were maximally decreased by 74 %, 32 % and 25 % at 4, 16 and 16 hours after injection, respectively. Serum hormone levels returned to pre-treatment values within two days after the last injection.</p><p>&nbsp;</p><p style="margin-right:9.4pt">Pharmacodynamic effects</p><p style="margin-right:9.4pt">&nbsp;</p><p style="margin-right:8.3pt">In patients undergoing controlled ovarian stimulation the median duration of Orgalutran treatment was 5 days. During Orgalutran treatment the average incidence of LH rises (&gt;10 IU/l) with concomitant progesterone rise (&gt;1 ng/ml) was 0.3 - 1.2 % compared to 0.8 % during GnRH agonist treatment.</p><p style="margin-right:9.4pt">There was a tendency towards an increased incidence of LH and progesterone rises in women with a higher body weight (&gt;80 kg), but no effect on clinical outcome was observed. However, based on the small number of patients treated so far, an effect can not be excluded.</p><p style="margin-right:9.4pt">In case of a high ovarian response, either as a result of a high exposure to gonadotrophins in the early follicular phase or as a result of high ovarian responsiveness, premature LH rises may occur earlier than day 6 of stimulation. Initiation of Orgalutran treatment on day 5 can prevent these premature LH rises without compromising the clinical outcome.</p><p>&nbsp;</p><p style="margin-right:8.3pt">Clinical efficacy and safety</p><p style="margin-right:8.3pt">&nbsp;</p><p style="margin-right:8.3pt">In controlled studies of Orgalutran with FSH, using a long protocol of GnRH agonist as a reference, treatment with the Orgalutran regimen resulted in a faster follicular growth during the first days of stimulation but the final cohort of growing follicles was slightly smaller and produced on average less oestradiol. This different pattern of follicular growth requires that FSH dose adjustments are based on the number and size of growing follicles, rather than on the amount of circulating oestradiol. Similar comparative studies with corifollitropin alfa using either a GnRH antagonist or long agonist protocol have not been performed.</p><p style="margin-right:8.3pt">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:8.3pt">Pharmacokinetic parameters after multiple subcutaneous dosing of Orgalutran (once daily injection) were similar to those after a single subcutaneous dose. After repeated dosing 0.25 mg/day steady-state levels of approximately 0.6 ng/ml were reached within 2 to 3 days.</p><p style="margin-right:8.3pt">&nbsp;</p><p style="margin-right:8.3pt">Pharmacokinetic analysis indicates an inverse relationship between bodyweight and serum concentrations of Orgalutran.</p><p style="margin-right:8.3pt">&nbsp;</p><p style="margin-right:8.3pt"><u>Absorption</u></p><p style="margin-right:8.3pt">After a single subcutaneous administration of 0.25 mg, serum levels of ganirelix rise rapidly and reach peak levels (Cmax) of approximately 15 ng/ml within 1 to 2 hours (tmax).. The bioavailability of Orgalutran following subcutaneous administration is approximately 91 %.</p><p>&nbsp;</p><p style="margin-right:8.3pt"><u>Biotransformation</u></p><p style="margin-right:8.3pt">The major circulating component in plasma is ganirelix. Ganirelix is also the main compound found in urine. Faeces only contain metabolites. The metabolites are small peptide fragments formed by enzymatic hydrolysis of ganirelix at restricted sites. The metabolite profile of Orgalutran in humans was similar to that found in animals.</p><p style="margin-right:8.3pt">&nbsp;</p><p style="margin-right:8.3pt"><u>Elimination</u></p><p style="margin-right:8.3pt">The elimination half-life (t&frac12;) is approximately 13 hours and clearance is approximately 2.4 l/h. Excretion occurs via faeces (approximately 75 %) and urine (approximately 22 %)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:8.3pt">Preclinical data reveal no special hazard for humans based on safety pharmacology, repeated dose toxicity and genotoxicity.</p><p>&nbsp;</p><p style="margin-right:8.3pt">Reproduction studies carried out with ganirelix at doses of 0.1 to 10 mg/kg/day subcutaneously in the rat and 0.1 to 50 mg/kg/day subcutaneously in the rabbit showed increased litter resorption in the highest dose groups. No teratogenic effects were observed.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:34.1pt; text-indent:-28.3pt"><!--[if !supportLists]--><strong>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>List of excipients</strong></p><p><strong>&nbsp;</strong></p><p style="margin-right:363.2pt">Acetic acid; Mannitol;</p><p>Water for injections.</p><p>The pH may have been adjusted with sodium hydroxide and acetic acid.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:8.3pt">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Do not freeze.</p><p>Store in the original package, in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:27.3pt; text-align:justify">Disposable pre-filled syringes (siliconised type I glass), containing 0.5 ml of sterile, ready for use, aqueous solution closed with a rubber piston that does not contain latex. Each pre-filled syringe is affixed with a needle <strong>closed by a needle shield of natural rubber latex. </strong>(See section 4.4.)</p><p>&nbsp;</p><p style="margin-right:198.75pt">Supplied in cartons containing 1 or 5 pre-filled syringes. Not all pack sizes may be marketed.</p><p style="margin-right:198.75pt">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:8.85pt">Inspect the syringe before use. Use only syringes with clear, particle-free solutions and from undamaged containers.</p><p style="margin-left:5.75pt; margin-right:8.85pt">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder
Merck Sharp & Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU
United Kingdom

Manufacturer
Vetter Pharma- Fertigung GmbH & Co. KG, Schutzenstrasse 87, 99 and 101, 88212, Ravensburg, Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jan 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>